Along with our data, these collective observations reinforce the premise for ongoing phase 2 trials combining tocilizumab, an anti-IL-6R targeted antibody with ICIs in melanoma (NCT03999749) and NSCLC (NCT04691817). Here, IL6R is linked to non-small cell lung carcinoma.